Loading quotes...

Forecast

The analysts' average price target is €64.48 (+6.63%). The median is €62.69 (+3.67%).

Buy	7
Hold	0
Sell	0

Discussions in the community

There is no discussion about this asset yet.

Start discussion

News Go to news feed

Eton Pharmaceuticals focuses on optimized specialty drugs for rare pediatric and metabolic diseases

Eton Pharmaceuticals avoids costly active ingredient research by optimizing and exclusively marketing proven drugs for rare pediatric and metabolic conditions. New products are sold through the existing sales network to the same specialist physicians, allowing revenues to grow faster than operating costs. The company has reached profitability and plans to achieve long-term EBITDA margins above current levels through organic product expansion and targeted acquisitions. » More on finanzen.net
Eton Pharmaceuticals hits record high of $64.29 after strong Q2 results

Eton Pharmaceuticals’ stock rose to a record high of $64.29, bringing its market capitalization to about $1.81 billion. Over the past year the share price gained 271.39%, and revenue increased 81% over the last twelve months. In Q2 2026 adjusted EPS of $0.43 (consensus $0.15) and revenue of $37.6 million (expectation $26.88 million) beat estimates; InvestingPro nonetheless rates the stock as overvalued. » More on de.investing.com
Eton Pharmaceuticals hits record high of $55.07 after strong Q2

Eton Pharmaceuticals shares climbed to a record high of $55.07 and are currently trading at $54.43, well above the 52-week high of $50.18. In Q2 2026 the company reported adjusted earnings per share of $0.43 (expectation $0.15) and a record revenue of $37.6 million, driven by margin expansion and stronger sales in the rare diseases segment. Market capitalization is about $1.12 billion, trailing-12-month revenue growth is nearly 80%, while InvestingPro rates the stock as overvalued relative to its fair value. » More on de.investing.com
Eton Pharmaceuticals jumps after record results and upward guidance

Eton Pharmaceuticals reported Q2 2026 revenue of $37.6 million, well above analyst estimates of $26.88 million, and adjusted EPS of $0.43 versus $0.15 expected. Management raised its 2026 revenue forecast to more than $145 million and showed strong margin improvement: adjusted EBITDA rose to $16.2 million and the EBITDA margin to 43%. H.C. Wainwright reaffirmed its buy rating and raised the price target to $65. The company pointed to pipeline catalysts such as FDA Fast Track designation for AMGLIDIA and the acquisition of hemangioma candidate ASN-001; the stock jumped in after-hours trading toward its 52-week high. » More on de.investing.com
Eton Pharmaceuticals secures US rights to topical hemangioma therapeutic ASN-001

Eton Pharmaceuticals licensed US rights to ASN-001, a topical timolol gel for the treatment of proliferating superficial infantile hemangiomas. In a Phase II/III study with 168 patients, ASN-001 produced clearance or near‑complete clearance at 24 weeks in 56% (twice daily) and 42% (three times daily) of users versus 15% with placebo. Eton plans a bioavailability bridging study and aims to submit a New Drug Application in the second half of 2027; if approved the product would be the first FDA‑approved topical therapy and is patented through 2044. » More on de.investing.com

Financials

In the last quarter, ETON PHARMACEUTIC had revenue of €51.14M and net profit of €31.12M

(EUR)	September 2026	YoY
Revenue	51.14M	167.21%
Gross profit	39.11M	484.32%
Net profit	31.12M	1,995.16%
EBITDA	21.86M	9,543.85%

Fundamentals

Metric	Value
Market capitalization	€1.45B
Number of shares	28.58M
52-week high/low	€59.44 - €12.78
Dividends	No
Beta	0.83
P/E ratio	31.99
PEG ratio	0.00
P/B ratio	18.62
P/S ratio	11.44

Company profile

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; and Rezipres, a ready-to-use formulation of a molecule that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. It also offers Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; EPRONTIA, a liquid formulation of topiramate; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. In addition, the company develops Zonisamide Oral Suspension for the treatment of partial on-set seizures; Lamotrigine for Oral Suspension for the treatment of partial on-set seizures; cysteine injection; dehydrated alcohol injection; and Zeneo hydrocortisone autoinjector. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.